Sunshine Biopharma logo

Sunshine Biopharma(NASDAQ) SBFMW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-92%
5 YearN/A
1 Year-75%
1 Month+55%
$0.05
+60.00%
+0.02Today
Sunshine Biopharma last closing stock price
MetricPriceDate
Last closeUSD 0.052026-10-12
Sunshine Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+90.48%USD 0.032026-10-05
1 month+54.84%USD 0.032026-09-02
3 month+19.7%USD 0.042026-07-10
Year to date-74.74%USD 0.192025-12-30
1 year-74.97%USD 0.192025-10-10
3 year-77.25%USD 0.212023-10-09
Since inception-92%USD 0.602022-02-15

Sunshine Biopharma Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$35.35M

Net Income (TTM)

-$5.83M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.28 (Average)

Price

$0.05

Volume

1,000

Open

$0.05

Previous Close

$0.05

Daily Range

$0.05 - $0.05

52-Week Range

$0.02 - $0.65

Estimated Earnings Date

Nov 10, 2026

SBFMW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sunshine Biopharma

Sunshine Biopharma, Inc. is a pharmaceutical and nutritional supplement company focused on developing innovative anticancer drugs. The company’s pipeline includes promising compounds like Adva-27a and SBFM-PL4, targeting various cancers and viral infections.

Products and Services
  • Adva-27a, an anticancer drug in development
  • SBFM-PL4, an anti-coronavirus treatment
  • Nutritional supplements, including Essential 9 and Essential Calcium-Vitamin D
Growth Outlook
  • Recent revenue growth of 14.5% from Q1 to Q2 2026
  • Strong cash position with $13.7 million in cash as of June 2026
  • Licensing agreement with the University of Georgia to enhance drug development
Financial Highlights
  • Q2 2026 revenue of $9.26 million, up from $8.09 million in Q1
  • Gross profit margin of 26.2% in Q2 2026
  • Current ratio of 5.46, indicating strong liquidity
Sunshine Biopharma, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry. The company is dedicated to addressing significant medical needs through its innovative drug development efforts. The recent growth in revenue and strong cash position suggest a positive trajectory for the company. The licensing agreement with the University of Georgia further enhances its potential for success in drug development. Investors may find the company's focus on anticancer therapies and nutritional supplements appealing, especially given the increasing demand for effective treatments in these areas.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Headquarters

Fort Lauderdale, FL 33301, US

SBFMW Financials

Key Financial Metrics (TTM)

Gross Margin

29.80%

Operating Margin

-14.71%

Net Income Margin

-16.50%

Return on Equity

-24.23%

Return on Capital

-18.78%

Return on Assets

-17.34%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

1.00K

Avg. Volume

2.77K

Financials (TTM)

Gross Profit

$10.53M

Operating Income

-$5.20M

EBITDA

-$5.26M

Operating Cash Flow

-$5.33M

Capital Expenditure

$736.10K

Free Cash Flow

-$4.60M

Cash & ST Invst.

$13.75M

Total Debt

$678.34K

Sunshine Biopharma Performance Analysis

Sunshine Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-300.1%
Q42025-12-31-8.9%
Q12026-03-31-5.7%
Q22026-06-3014.5%
Sunshine Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3097.6%
Q42025-12-31-142.1%
Q12026-03-3145.7%
Q22026-06-3054.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$9.26M

-1.6%

Gross Profit

$2.43M

-29.1%

Gross Margin

26.20%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

50

N/A

Net Income

-$1.56M

+11.7%

EBITDA

-$1.53M

+19.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$13.75M

+33.4%

Total Debt

$678.34K

-27.0%

Accounts Receivable

$4.04M

+12.5%

Inventory

$12.12M

-6.9%

Long Term Debt

$475.82K

-32.7%

Short Term Debt

$202.52K

-9.0%

Return on Assets

-17.34%

N/A

Return on Invested Capital

-18.56%

N/A

Free Cash Flow

-$912.85K

+49.9%

Operating Cash Flow

-$917.98K

+27.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BFRIWBiofrontera Inc.
$0.01-20.00%
BHNGFBhang Inc.
$0.00+0.00%
IONKFIonic Brands Corp.
$0.00+0.00%
MDVLQMedAvail Holdings, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About SBFMW

What is the current price of Sunshine Biopharma?

Sunshine Biopharma is trading at $0.05 per share.

What is the 52-week range for Sunshine Biopharma?

Over the past 52 weeks, Sunshine Biopharma has traded between $0.02 and $0.65.

How much debt does Sunshine Biopharma have?

Sunshine Biopharma total debt is unavailable.

How much cash does Sunshine Biopharma have on hand?

Sunshine Biopharma does not have cash on hand data available.

What is Sunshine Biopharma’s dividend yield?

Sunshine Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.